Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility | MicrobiomeTrials← Back to trialsNCT04244877
Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility
WITHDRAWNPHASE3INTERVENTIONAL
Trial Details
Start: 2021-09-15Est. Completion: 2023-05-01
Enrollment target: 0 participants Other microbiome trials you might be interested in
Liver Diseases
This study integrates and evaluates a series of novel MRI methods for quantifying blood perfusion and tissue microstruct…
Madison, United StatesEst. completion May 2029
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
The newly adapted definition for MASLD includes evidence for hepatic steatosis by imaging or biopsy with at least one of…
Sohag, EgyptEst. completion Jan 1, 2027
Post-hepatectomy Hypoalbuminemia
Rice-derived recombinant human serum albumin (OsrHSA) possesses an identical primary, secondary, and higher-order struct…
Wuhan, ChinaEst. completion Jul 7, 2027